This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

His expertise and leadership are essential as we continue to industrialize our design-build-test process for drug discovery and work to bring #miniprotein medicines to patients across many diseases.

James has been a pivotal force in building our protein engineering approach, and as #CTO, he'll be driving the expansion of our core technology platform, integrating machine learning, synthetic biology, robotics, and large-scale data analysis to create entirely novel protein therapeutics

and more coverage from Endpoints News @endpts.com

endpts.com/bms-inks-dea...

You can read more about our exciting new collaboration with Bristol Myers Squibb in this coverage from Fierce Biotech
www.fiercebiotech.com/biotech/bris...